When combination therapy (ETV + GLP-26) was administered between days 0 and 35, virus suppression was observed until the combination therapy was withdrawn, and only then some virus rebound was seen, but this did not reach statistical significance ( p > 0.05) ( Figure 3 A).
← all excerpts
Studies on the Efficacy, Potential Cardiotoxicity and Monkey Pharmacokinetics of GLP-26 as a Potent Hepatitis B Virus Capsid Assembly Modulator.
1
0.0500
0.0500